In cancer research, RIC8, functioning as GEF and chaperone for Gα, has been proposed as a potential therapeutic target, since it has been shown that constitutive activation of Gα by somatic mutations leads to development of various cancers [106]. This evidence concerns the gene RIC8A and cancer.